Annals of surgical oncologyHumansPoly(ADP-ribose) Polymerase InhibitorsOvarian NeoplasmsFemaleClinical Trials
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors According to Clinical Risk in Newly Diagnosed, Advanced Ovarian Cancer: A Meta-analysis of Phase III Clinical Trials.
Gillian Reid-Schachter, Helena C Bartels, Donal J Brennan
Published: 202610.1245/s10434-025-18400-8
Abstract
BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy improves progression-free survival (PFS) in patients with advanced ovarian cancer, with greatest benefit observed in patients with BRCA alterations and homologous recombinat…
Preview only. Read the full abstract at the source